Study Title

Phase 2 Study of Repeat-dose [177Lu]Ludotadipep Treatment for Metastatic Castration-resistant Prostate Cancer

Study Details

Description:

100 mCi of [177Lu]Ludotadipep, the dose determined in the phase 1 clinical trial (FC705-1), was administered repeatedly up to 6 times at intervals of 8 weeks (±2 weeks) to patients with metastatic castration resistant prostate cancer (mCRPC) in order to assess the safety and efficacy.

Sponsor:

FutureChem

Contacts:

ChanSoo Park, Ph.D

chansoo.park@futurechem.co.kr

+82-70-5066-2479

Sanghee Hwang

shhwang@dtnsm.co.kr

070-4916-7975

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468